Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Acute Heart Failure
9%
Acute Myocardial Infarction
14%
All-cause Mortality
13%
Antiarrhythmic Drugs
9%
Arrhythmia
8%
Atrial Fibrillation
100%
Cardiac Function
9%
Cardiovascular Mortality
10%
Cardioverter-defibrillator Implantation
15%
CARISMA
14%
Catheter Ablation
14%
Copenhagen City Heart Study
9%
Coronary Artery Disease
7%
Echocardiography
8%
Empagliflozin
9%
Extended Follow-up
9%
Furosemide
9%
Global Longitudinal Strain
8%
Hazard Ratio
16%
Heart Failure
9%
Heart Failure Patients
11%
High Burden
7%
Implantable Cardioverter-defibrillator
20%
Insulin
9%
Interleukin-6
14%
Ischemic Heart Failure
9%
Left Ventricular Ejection Fraction
9%
Left Ventricular Systolic Dysfunction
11%
Left Ventricular Systolic Function
9%
Major Adverse Cardiovascular Events
12%
Mortality Hazard
7%
N-terminal pro-B-type Natriuretic Peptide (NT-proBNP)
8%
New-onset Atrial Fibrillation
14%
Non-ischemic Systolic Heart Failure
16%
P-wave Velocity
9%
Paroxysmal Atrial Fibrillation
8%
Permanent Atrial Fibrillation
15%
Persistent Atrial Fibrillation
19%
Plasma Aldosterone Concentration
9%
Randomized Clinical Trial
14%
Randomized Controlled Trial
10%
Rate Control
9%
Remote Dielectric Sensing
8%
Sinus Rhythm
9%
Soluble Urokinase Plasminogen Activator Receptor (suPAR)
17%
Third-degree Atrioventricular Block
9%
Type 1 Diabetes Mellitus (T1DM)
14%
Type 2 Diabetic Patients
9%
Type I Diabetes
14%
Ventricular Arrhythmia
8%
Medicine and Dentistry
Ablation
9%
Acute Coronary Syndrome
10%
Acute Decompensated Heart Failure
9%
Acute Heart Infarction
14%
All Cause Mortality
14%
Amino Terminal Sequence
9%
Antiarrhythmic Drug
9%
Apoplexy
11%
Atrial Fibrillation
78%
Biological Marker
13%
Brain Natriuretic Peptide
7%
Cardiac Dysrhythmia
7%
Cardiovascular Disease
21%
Cardiovascular System
30%
Congestive Heart Failure
23%
Coronary Artery Disease
7%
Diuresis
7%
Echocardiography
9%
Electrocardiogram
10%
Electrocardiography
8%
Empagliflozin
9%
Faintness
9%
Fatty Acid
7%
Furosemide
9%
Hazard Ratio
14%
Heart Function
10%
Heart Left Ventricle Ejection Fraction
10%
Heart Muscle Ischemia
9%
Implantable Automatic Defibrillator
24%
Insulin
9%
Insulin Dependent Diabetes Mellitus
14%
Interleukin 6
12%
Left Atrial Volume
7%
Left Ventricular Systolic Dysfunction
11%
Morbidity
11%
Multidetector Computed Tomography
9%
Myocardial Infarction
15%
Natriuretic Factor
7%
New-Onset Atrial Fibrillation
14%
P Wave
9%
Patient with Type 2 Diabetes
9%
Permanent Atrial Fibrillation
13%
Prevalence
7%
Randomized Clinical Trials
9%
Sinus Rhythm
10%
Systematic Review
9%
Systolic Function
11%
Systolic Heart Failure
16%
Third-Degree Atrioventricular Block
10%
Urokinase Receptor
16%